A new medical cannabis company called Katexco Pharmaceuticals aims to develop oral therapies that harness the brain’s endocannabinoid and nicotine receptors to treat inflammatory diseases such as multiple sclerosis.

Co-founded by two Stanford University researchers — Jonathan Rothbard, PhD, and Lawrence Steinman, MD — Katexco will leverage their expertise in immunological therapy and use a synergistic approach to use the body’s natural system to curb inflammation.

In addition to multiple sclerosis, Katexco will work to treat gastrointestinal conditions such as Crohn’s disease, and gout.

Click here to read the complete article

Vijaya Iyer ~ Multiple Sclerosis News Today ~